Ecs Botanics Holdings logo
ECS
Pharmaceuticals, Biotechnology & Life Sciences

ECS Botanics Holdings

Short interest
0.13%
+0.12 pp 30d
as of 27 Feb 2024
Reported shorts
1.5M
Shares on issue
1.107B

ECS Botanics Holdings (ECS) financials

Results, ratios and statements

Latest result

Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency

Revenue
$21.4M (source: ASX (Markit))vs $19.5M (source: ASX (Markit)) (FY25)
ASX (Markit), as at 14 Oct 2026
NPAT
−$1.9M (source: ASX (Markit))vs −$5.7M (source: ASX (Markit)) (FY25)
ASX (Markit), as at 14 Oct 2026
EPS (diluted)
−$0.001 (source: Derived: trailing 12 months at year end)vs −$0.004 (source: Derived: trailing 12 months at year end) (FY25)
Derived: trailing 12 months at year end, as at 14 Oct 2026
Rev YoY
+9.9%FY
EPS YoY
n/aTTM
  • ASX (Markit)
  • Derived: trailing 12 months at year end

Summary of Appendix 4E & Annual Report, 28 Aug 2026

ECS Botanics reported revenue of $21.4m for FY2026, up 10% from $19.5m, while net loss narrowed 67% to $1.9m from $5.7m. No dividend was declared. The company achieved positive EBITDA of $0.6m and positive operating cash flow of $0.5m, and expects to continue extracting value from its cultivation and manufacturing platform in FY2027.

Automated summary of the filing; the filing itself is the record.

Key ratios

Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 15 Oct 2026

Gross margin
58.1%
Operating margin
2.4%
Net margin
−8.9%
FCF margin
−2.4%
ROE
n/a
ROA
n/a
FCF conversion
n/a
Net debt (excl. leases)
n/a
Net debt / EBITDA
n/a
Current ratio
n/a
Interest cover
1.0×
Cash dividends paid / net profit
n/a
Market cap
n/a (no share count we can vouch for)
P/E
n/a
P/B
n/a (no share count we can vouch for)

Ratios use the reporting currency (AUD); market cap is in AUD. Sources: ASX (Markit) and Derived: trailing 12 months at year end, as at 14 Oct 2026.

Financial statements

Figures in AUD, the reporting currency; Yahoo Finance unless marked

ECS income, newest period first, figures in AUD
Line itemFY26FY25FY24FY23
Revenue$21.4M (source: ASX (Markit))$19.5M (source: ASX (Markit))$20.0M$15.4M
Gross profit$12.4M (source: Derived: trailing 12 months at year end)n/a$9.1M$6.0M
Operating income$520.0K (source: Derived: trailing 12 months at year end)n/a$1.7M−$68.8K
EBITDA$581.9K (source: Derived: trailing 12 months at year end)n/a$3.3M$1.6M
EBIT−$515.7K (source: Derived: trailing 12 months at year end)n/a$2.0M$531.9K
Interest expense$514.7K (source: Derived: trailing 12 months at year end)n/a$61.8K$40.5K
Pretax income−$1.0M (source: Derived: trailing 12 months at year end)n/a$1.9M$491.4K
Tax$874.8K (source: Derived: trailing 12 months at year end)n/a−$70.4K$0
NPAT−$1.9M (source: ASX (Markit))−$5.7M (source: ASX (Markit))$2.0M−$81.8K
Net interest income−$514.7K (source: Derived: trailing 12 months at year end)n/a−$26.4K−$16.8K
EPS basic−$0.001 (source: Derived: trailing 12 months at year end)−$0.004 (source: Derived: trailing 12 months at year end)$0.002$0.000
EPS diluted−$0.001 (source: Derived: trailing 12 months at year end)−$0.004 (source: Derived: trailing 12 months at year end)$0.002$0.000
Sharesn/an/a1.29B1.11B
  • ASX (Markit)
  • Derived: trailing 12 months at year end